As the cell and gene therapies market evolves, CDMOs and pharmaceutical companies aim to adapt to the rising demands and serve larger patient populations.
Aptar Group acquires two pharmaceutical services companies, Nanopharm and Gateway Analytical, to boost its analytical, testing, and development capabilities.
TrialAssure’s new online portal enables sponsors to publicly share plain language clinical trial summaries – as the industry faces continued pressure to post study results.
Insys announces that it will file for Chapter 11 bankruptcy following the settlement of a legal case regarding its sales tactics for its opioid-based pain killer.
Covance seeks an Economic Revitalization Area designation at its Indianapolis, IN-based site, at which the company looks to expand its sample storage capacity and add space “dedicated to innovation" as part of an $11.8m construction project.
Achaogen sells majority of assets for a grand total of $16m ahead of bankruptcy, in another indication of the difficulties of relying on antibiotics for revenue.
Competitive costs, improving infrastructure, and a high burden of disease are increasing the demand for clinical research in Africa, says CRO, which has partnered with a US-based firm to expand its service offerings.
Amgen and Takeda will join fellow big pharma companies Sanofi, GSK, and Janssen, in working to progress Feldan’s intracellular drug delivery technology.
Longboat Clinical is partnering with the Avoca Quality Consortium to provide quality management tools to hospitals and clinics conducting clinical studies.
ElevateBio’s BaseCamp facility will provide “bench-to-bedside” services to its portfolio and partner companies – as the demand for cell and gene therapy CMOs “far outweighs the capacity,” says CEO.
LabCorp and Quest Diagnostics this week disclosed unauthorized activity on the web payment page of the companies’ billing collections service provider.
The global oncology market last year set several records, though the industry continues to struggle with long development timelines, which in 2018 averaged 10.5 years from patent filing to regulatory approval and launch, according to a recent Iqvia report.
Atomwise signs a multi-year agreement with Eli Lilly and Company through which it will apply its patented artificial intelligence technology to support Lilly’s preclinical drug discovery efforts.
Broader clinical trial eligibility criteria would double patient numbers in lung cancer studies, according to a new report from ASCO, which has been leading efforts to expand access to oncology clinical trials.
Gilead and HitGen have signed a drug discovery collaboration – one of several recently announced agreements as HitGen sees increased demand for its technology, says CSO.
The US FDA approves Merck’s application to expand the label of Zerbaxa for the treatment of hospital-acquired infections to address ‘global challenge’ of AMR.
The private equity firm Ampersand Capital has acquired Vibalogics with plans to increase development and manufacturing capabilities for complex viral products.
The online marketplace for outsourced R&D services Scientist.com partners with 5AM Ventures to help researchers save time and money – as the industry is "caught between a rock and a hard place," says CEO.
Lonza announces that its Specialty Ingredients business will operate independently by ‘mid-2020’ and will cut away approximately 130 roles at the same time.
This month’s roundup includes the first CFO for CytoReason, a new CEO at Certara and Factory-CRO, as well as an expanded leadership team at BioDuro, among other people on the move in May.
Parexel today unveiled its Oncology Center of Excellence as well as a new “early advisory service” focused on study design, regulatory strategy, and market access.
Risk-based monitoring should be described as a “best practice,” says ACRO, which recently released a survey that found the majority of new trial starts in 2018 employed some form of RBM.
PPD’s Evidera business unit is set to acquire Medimix International, a global technology company with a real-world evidence service offering that includes access to patient-level data, data analytics, and visualization capabilities.
EMA assembles pharmaceutical developers to strengthen antimicrobial pipelines while, in the meantime, a study found the world’s rivers dangerously contaminated.
Last year saw heightened market volatility, marked by international trade disputes, regulatory unrest, and a general feeling of uncertainty – but 2019 is off to a strong start with several multi-billion dollar deals.
Translational research faces new challenges – and opportunities – with the rapid growth in precision medicine and new drug modalities, as the industry looks to quickly bring new treatments to patients.
Vetter’s German sites will be supplied with only CO2 neutral energy from renewable energy sources as the company continues to work towards greater sustainability.
